Alembic Pharmaceuticals announced that Aleor Dermaceuticals, a 60:40 Joint Venture between Alembic Pharmaceuticals (Alembic) and Orbicular Pharmaceutical Technologies (Orbicular), has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection carried out by them at Aleor's Formulation Facility at Karakhadi, Gujarat, India during the
period from 15 September, 2019 to 20 September, 2019.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
